MetLife Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.86M | Buy |
113,825
+4,900
| +4% | +$163K | 0.02% | 786 |
|
|
2026
Q1 | $3.28M | Buy |
108,925
+2,600
| +2% | +$83.6K | 0.02% | 810 |
|
|
2025
Q4 | $3.32M | Sell |
106,325
-400
| -0.4% | -$9.85K | 0.02% | 812 |
|
|
2025
Q3 | $2.16M | Hold |
106,725
| – | – | 0.01% | 1052 |
|
|
2025
Q2 | $1.79M | Sell |
106,725
-14,100
| -12% | -$228K | 0.01% | 1045 |
|
|
2025
Q1 | $1.86M | Sell |
120,825
-12,600
| -9% | -$225K | 0.01% | 1071 |
|
|
2024
Q4 | $2.94M | Buy |
133,425
+38,400
| +40% | +$699K | 0.02% | 847 |
|
|
2024
Q3 | $1.71M | Sell |
95,025
-10,100
| -10% | -$177K | 0.01% | 1101 |
|
|
2024
Q2 | $1.71M | Buy |
105,125
+41,872
| +66% | +$645K | 0.01% | 1056 |
|
|
2024
Q1 | $893K | Hold |
63,253
| – | – | 0.01% | 1360 |
|
|
2023
Q4 | $660K | Hold |
63,253
| – | – | ﹤0.01% | 1524 |
|
|
2023
Q3 | $645K | Hold |
63,253
| – | – | 0.01% | 1478 |
|
|
2023
Q2 | $476K | Hold |
63,253
| – | – | ﹤0.01% | 1719 |
|
|
2023
Q1 | $560K | Sell |
63,253
-12,500
| -17% | -$124K | ﹤0.01% | 1578 |
|
|
2022
Q4 | $691K | Hold |
75,753
| – | – | 0.01% | 1432 |
|
|
2022
Q3 | $611K | Hold |
75,753
| – | – | 0.01% | 1490 |
|
|
2022
Q2 | $570K | Hold |
75,753
| – | – | ﹤0.01% | 1567 |
|
|
2022
Q1 | $711K | Hold |
75,753
| – | – | ﹤0.01% | 1551 |
|
|
2021
Q4 | $607K | Hold |
75,753
| – | – | 0.01% | 1407 |
|
|
2021
Q3 | $738K | Hold |
75,753
| – | – | 0.01% | 1286 |
|
|
2021
Q2 | $750K | Hold |
75,753
| – | – | 0.01% | 1336 |
|
|
2021
Q1 | $874K | Sell |
75,753
-13,400
| -15% | -$154K | 0.01% | 1221 |
|
|
2020
Q4 | $860K | Hold |
89,153
| – | – | 0.01% | 1203 |
|
|
2020
Q3 | $803K | Buy |
89,153
+11,200
| +14% | +$118K | 0.01% | 1139 |
|
|
2020
Q2 | $961K | Hold |
77,953
| – | – | 0.01% | 1055 |
|
|
2020
Q1 | $700K | Hold |
77,953
| – | – | 0.01% | 1053 |
|
|
2019
Q4 | $764K | Hold |
77,953
| – | – | 0.01% | 1232 |
|
|
2019
Q3 | $536K | Hold |
77,953
| – | – | 0.01% | 1384 |
|
|
2019
Q2 | $720K | Sell |
77,953
-147,206
| -65% | -$1.77M | 0.01% | 1276 |
|
|
2019
Q1 | $3.53M | Buy |
225,159
+154,806
| +220% | +$2.73M | 0.01% | 990 |
|
|
2018
Q4 | $1.08M | Hold |
70,353
| – | – | 0.01% | 986 |
|
|
2018
Q3 | $1.52M | Hold |
70,353
| – | – | 0.02% | 967 |
|
|
2018
Q2 | $1.71M | Buy |
70,353
+7,600
| +12% | +$155K | 0.02% | 840 |
|
|
2018
Q1 | $1.07M | Sell |
62,753
-7,700
| -11% | -$150K | 0.01% | 976 |
|
|
2017
Q4 | $1.33M | Buy |
+70,453
| New | +$1.06M | 0.02% | 917 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
MetLife Investment Management's TEVA Position: Q2 2026 in Review
MetLife Investment Management increased its Teva Pharmaceuticals (TEVA) stake by 4.5% in Q2 2026, buying an estimated $163K and bringing the position to 113,825 shares worth $3.86M. The position accounts for 0.02% of the portfolio, ranked #786.
MetLife Investment Management first reported a position in TEVA in Q4 2017 and has held it in 35 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- MetLife Investment Management held 113,825 shares of Teva Pharmaceuticals worth $3.86M as of Q2 2026.
- MetLife Investment Management bought 4,900 Teva Pharmaceuticals shares in Q2 2026, an estimated $163K.
- Teva Pharmaceuticals made up 0.02% of MetLife Investment Management's portfolio in Q2 2026, its #786 holding.
- MetLife Investment Management first reported a position in Teva Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.